DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
DBV Technologies S.A.NASDAQ: DBVT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$45.9M, compared with -$25.04M a year earlier. Trailing-twelve-month EBITDA was -$159.48M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$87.95M (+36.9%) for the fiscal year ending Dec 2026, a step up from the -25.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$45.9M-5.3% QoQ
- Last fiscal yearDec 2025
- -$139.32M-25.5% YoY
- LTMMar 2026
- -$159.48M-49.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -83.3% | +89.5% | +172.8 pp |
| 1 year | -25.5% | +36.9% | +62.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (139.32M) USD
- Year-over-year change
- -25.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (139.32M) | -25.5% |
| FY2024 | 2024-12-31 | (110.99M) | -75.4% |
| FY2023 | 2023-12-31 | (63.27M) | +17.5% |
| FY2022 | 2022-12-31 | (76.68M) | +15.9% |
| FY2021 | 2021-12-31 | (91.16M) | — |
EBITDA vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 EBITDA of -$159.48M is the 9th highest of the 11 companies compared; the peer median is -$81.67M.
- Its year-over-year change of -49.1% is the 7th highest of 10, against a peer median of -16.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.14M | +92.4% | — | 2.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M | — | — | — |
| LTM Mar 2026 | -$51.11M | -57.3% | — | 75.1% | |
| LTM Mar 2026 | -$71.29M | -16.9% | — | — | |
| LTM Mar 2026 | -$78.15M | +14.5% | — | 2034.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$85.19M | +20.5% | — | — |
| LTM Mar 2026 | -$88.27M | +2.7% | — | 245200.0% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M | -65.1% | — | — |
| LTM Mar 2026 | -$159.48M | -49.1% | — | — | |
| LTM Mar 2026 | -$165.68M | -74.6% | — | — | |
| LTM Mar 2026 | -$193.41M | -17.1% | — | — | |
| Peer median (excluding DBVT) | -$81.67M | -16.9% | — | 1054.5% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.71M | 4.8M | 15.73M | 0 | 0 |
| Cost of Revenue | 9.27M | 20.3M | 0 | 6.81M | 17.67M |
| Gross Profit | (3.57M) | (15.5M) | 15.73M | (6.81M) | (17.67M) |
| Gross Margin | -62.5% | -322.9% | 100.0% | — | — |
| Research & Development | 70.34M | 75.5M | 60.22M | 89.9M | 116.68M |
| Selling, General & Admin | 23.83M | 17.56M | 31.94M | 23.81M | 28.28M |
| Operating Expenses | 93.93M | 101.48M | 92.16M | 113.71M | 147.06M |
| Depreciation & Amortization | 8.38M | 20.3M | 13.16M | 6.81M | 7.73M |
| EBITDA | (91.16M) | (76.68M) | (63.27M) | (110.99M) | (139.32M) |
| EBITDA Margin | -1597.0% | -1597.5% | -402.3% | — | — |
| Operating Income | (98.61M) | (96.63M) | (76.43M) | (120.53M) | (147.06M) |
| Operating Margin | -1727.6% | -2013.1% | -486.0% | — | — |
| Interest Income | 521K | 406.29K | 3.71M | 2.73M | 601.86K |
| Interest Expense | 690K | 427K | 0 | 0 | 0 |
| Other Income / Expenses | 424K | 427K | 3.71M | 2.73M | 600K |
| Income Before Tax | (98.19M) | (96.2M) | (72.72M) | (117.8M) | (146.46M) |
| Pre-Tax Margin | -1720.2% | -2004.3% | -462.4% | — | — |
| Income Tax Expense | (381K) | 70K | 7K | (4.08M) | 491K |
| Net Income | (97.81M) | (96.3M) | (72.73M) | (113.72M) | (146.95M) |
| Net Margin | -1713.5% | -2006.3% | -462.4% | — | — |
| EPS (Basic) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| EPS (Diluted) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| Weighted Avg Shares | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
| Weighted Avg Shares (Diluted) | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.